# Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma

> **NCT01415752** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Eastern Cooperative Oncology Group** · enrollment: 373 (actual)

## Conditions studied

- Lymphoma
- Mantle Cell Lymphoma

## Interventions

- **BIOLOGICAL:** rituximab
- **DRUG:** Bendamustine
- **DRUG:** bortezomib
- **DRUG:** lenalidomide

## Key facts

- **NCT ID:** NCT01415752
- **Lead sponsor:** Eastern Cooperative Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2012-08-09
- **Primary completion:** 2023-02-25
- **Final completion:** 2031-09
- **Target enrollment:** 373 (ACTUAL)
- **Last updated:** 2025-04-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01415752

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01415752, "Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01415752. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*